Bioartificial livers: a review of their design and manufacture
Kahaer Tuerxun, Jianyu He, Irxat Ibrahim, Zainuer Yusupu, Abudoukeyimu Yasheng, Qilin Xu, Ronghua Tang, Aizemati Aikebaier, Yuanquan Wu, Maimaitituerxun Tuerdi, Mayidili Nijiati, Xiaoguang Zou, Tao Xu
Abstract
Acute liver failure (ALF) is a rapidly progressive disease with high morbidity and mortality rates. Liver transplantation and artificial liver (AL) support systems, such as ALs and bioartificial livers (BALs), are the two major therapies for ALF. Compared to ALs, BALs are composed of functional hepatocytes that provide essential liver functions, including detoxification, metabolite synthesis, and biotransformation. Furthermore, BALs can potentially provide effective support as a form of bridging therapy to liver transplantation or spontaneous recovery for patients with ALF. In this review, we systematically discussed the currently available state-of-the-art designs and manufacturing processes for BAL support systems. Specifically, we classified the cell sources and bioreactors that are applied in BALs, highlighted the advanced technologies of hepatocyte culturing and bioreactor fabrication, and discussed the current challenges and future trends in developing next-generation BALs for large-scale clinical applications.